GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include GTS-21 dihydrochloride and DMXB-Anabaseine. Its PubChem CID is 5310985.
Gts-21
| CAS No | 148372-04-7 |
|---|---|
| Molecular Formula | C19H20N2O2 |
| Molecular Weight | 308.4 g/mol |
| Synonyms | 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials.
The listed CAS number is 148372-04-7.
The listed molecular formula is C19H20N2O2.
The listed molecular weight is 308.4 g/mol.
3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine.
The source lists GTS-21 dihydrochloride and DMXB-Anabaseine.